^
    CANCER:

    Small Cell Lung Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    		0
    PD1 inhibitor
    pembrolizumab
    serplulimab
    sintilimab
    cisplatin
    		1
    DNA synthesis inhibitor
    temozolomide
    gemcitabine
    atezolizumab
    		2
    PD-L1 inhibitor
    durvalumab
    PD-L1 inhibitor
    avelumab
    irinotecan
    		3
    Topoisomerase I inhibitor
    topotecan
    nanoliposomal irinotecan
    olaparib
    		4
    PARP inhibitor
    ABT-888
    talazoparib
    5
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    6
    Tubulin polymerization promoter
    carboplatin
    7
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    8
    DNA replication inhibitor
    bendamustine
    9
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    10
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    cisplatin + irinotecan
    cisplatin + topotecan
    EGFR inhibitor
    		11
    EGFR inhibitor
    osimertinib
    gefitinib
    12
    WEE1 inhibitor
    AZD1775
    SC0191
    13
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    14
    CDK4 inhibitor, CDK6 inhibitor
    trilaciclib
    anlotinib
    		15
    Multi-tyrosine kinase inhibitor
    pazopanib
    ponatinib
    16
    CTLA4 inhibitor
    ipilimumab
    17
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    18
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + camrelizumab
    pembrolizumab + anlotinib
    19
    HER2 inhibitor
    trastuzumab
    20
    mTOR inhibitor, mTORC2 inhibitor
    AZD2014
    21
    RET inhibitor
    selpercatinib
    22
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    23
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    24
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide IV
    25
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + etoposide IV
    26
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    27
    RNA polymerase inhibitor, Alkylating agent, Apoptosis stimulant
    lurbinectedin
    28
    Chemotherapy
    CAV
    29
    Immunotherapy
    Immunotherapy
    30
    DLL3 inhibitor, CD3 agonist
    AMG 757
    BI 764532
    31
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    32
    DLL3 inhibitor, CD47 inhibitor
    PT217
    33
    Gene transference, PD-L1 inhibitor, Apoptosis stimulant, Immunomodulator, TUSC2 gene stimulant
    atezolizumab + quaratusugene ozeplasmid
    34
    VEGFR inhibitor, PDGFR inhibitor, Aurora kinase B inhibitor, CSF-1R inhibitor, c-KIT inhibitor, PDGFR α antagonist
    CS 2164
    35
    SIRPA antagonist, NRF2 activator, MYC inhibitor, NLRP3 inhibitor, CD47 inhibitor
    RRx-001
    36
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    37
    DNA synthesis inhibitor, PARP inhibitor
    temozolomide + ABT-888
    38
    DLL3-targeted antibody-drug conjugate, DNA replication inhibitor
    rovalpituzumab tesirine
    39
    PD-L1 inhibitor, PARP inhibitor
    atezolizumab + talazoparib
    40
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    41
    B7-H3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-7300
    42
    ATR inhibitor, RNA polymerase inhibitor, Alkylating agent, Apoptosis stimulant
    M6620 + lurbinectedin
    AZD6738 + lurbinectedin
    43
    p53 reactivator
    APR-246
    44
    Aurora kinase B inhibitor
    AZD1152
    AZD2811
    45
    SSTR2 inhibitor, α radiation emission
    RYZ101
    46
    MYC inhibitor
    ICX-101
    47
    EPCAM inhibitor, CD47 inhibitor
    VBI-003
    48
    EGFR inhibitor, Multi-tyrosine kinase inhibitor
    gefitinib + anlotinib
    49
    ALK inhibitor
    alectinib
    50
    BET inhibitor, PARP inhibitor
    talazoparib + GSK525762
    51
    Aurora kinase A inhibitor, WEE1 inhibitor
    AZD1775 + VIC-1911
    52
    FGFR inhibitor, AKT inhibitor
    futibatinib + TAS-117
    53
    CDK7 inhibitor
    YPN-005
    54
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    55
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    56
    mTOR inhibitor
    AZD8055
    57
    Arginase replacement
    BCT-100
    58
    VEGF-A inhibitor
    bevacizumab
    59
    c-KIT-targeted antibody-drug conjugate, Microtubule inhibitor
    NN3201
    LOP628
    60
    SEZ6-targeted antibody-drug conjugate, DNA minor groove binder
    ABBV-011
    No biomarker
    EGFR exon 19 deletion
    EGFR exon 19 mutation
    EGFR exon 19 deletion + EGFR T790M
    EGFR exon 21 mutation
    EGFR T790M
    EGFR L861Q
    EGFR G719C + EGFR E709V
    EGFR mutation
    PD-L1 expression
    PD-L1 negative
    TMB-H + PD-L1 expression
    PD-L1 elevation
    SLFN11 expression
    HLA-DQB1*03:01
    DLL3 expression
    DLL3 overexpression
    DLL3 positive
    SLFN11 overexpression
    SLFN11 underexpression
    DLL3 underexpression
    TMB-H
    RECQL mutation
    MCL1 underexpression
    IL2 elevation
    RECQL4 mutation
    RECQL5 mutation
    MRC1 expression
    RPA1 mutation
    CD276 overexpression
    WRN mutation
    CCL5 overexpression
    RB1 wild-type
    YAP1 underexpression
    ERCC1 overexpression
    MSI-H/dMMR
    GBP5 overexpression
    NTRK1 fusion
    RAD54L mutation
    RAD50 mutation
    NBN mutation
    BLM mutation
    MRE11A mutation
    MYC amplification
    MYCN amplification
    ATM deletion
    CDKN2A mutation + TP53 mutation
    RAD51C mutation
    RICTOR amplification
    MYCL amplification
    RAD51D mutation
    FGFR1 amplification + RAF1 amplification + MYC amplification
    NTRK2 fusion
    NTRK3 fusion
    HER-2 positive
    EML4-ALK fusion + TMB-L
    TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124*
    ALK fusion + ALK V1180L
    KIF5B-RET fusion
    RAD51B mutation
    RAD51 mutation
    RAD52 mutation
    MYC overexpression
    MYC expression
    ALK fusion + ALK G1202R
    RB1 mutation
    ALK rearrangement
    CDH1 overexpression
    CHEK1 overexpression + MYC overexpression
    CD47 expression + EPCAM expression
    ERCC5 overexpression
    CD47 expression
    VIM expression
    MMP9 overexpression
    TP53 mutation
    ARG2 underexpression
    CSMD3 mutation
    KIT positive
    ETV1 E462Q
    ETV1 P159S
    EGFR exon 19 deletion + PTEN K237Cfs*17
    FGFR1 amplification + RAF1 amplification + CDK6 amplification
    TNFA elevation
    EGFR exon 19 deletion + TP53 mutation + RB1 mutation
    SEZ6 expression
    KDM1A expression
    POU2F3 overexpression
    POU2F3 expression
    SSTR2 overexpression
    IL6 elevation
    FGFR1 amplification